Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-targeted siRNA
- Development stage
- Preclinical
- Lead developer
- Scintomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
PSMA-targeted siRNA (Scintomics/TUM) is a preclinical RNA interference (RNAi) therapeutic candidate developed by Scintomics GmbH in collaboration with the Technical University of Munich (TUM). The drug is designed to treat metastatic castration-resistant prostate cancer (mCRPC) by utilizing small interfering RNA (siRNA) molecules to silence specific oncogenic genes essential for tumor cell survival and proliferation. To ensure selective delivery to malignant tissues, the siRNA is conjugated to a high-affinity ligand that targets the Prostate-Specific Membrane Antigen (PSMA), a cell-surface protein highly overexpressed in advanced prostate cancer. This program leverages Scintomics' expertise in 'radiohybrid' (rhPSMA) technology, which typically allows for the exchange of diagnostic (e.g., F-18) and therapeutic (e.g., Lu-177, Ac-225) isotopes on a single molecular scaffold. In this context, the siRNA construct may be designed as a radiohybrid to enable dual-modality therapy or precision monitoring of drug delivery and biodistribution via PET imaging.
- Other names
- siRNA targeting PSMAPSMA-siRNA
02
Targets
PSMA (Prostate-specific membrane antigen)Membrane cofactor protein (CD46) mRNACD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PSMA-targeted siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-targeted siRNA.